


PHARMACEUTICAL 2017



Travere Therapeutics Inc. Rank 56 of 313







PHARMACEUTICAL 2017





Travere Therapeutics Inc. Rank 56 of 313

The relative strengths and weaknesses of Travere Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Travere Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 177% points. The greatest weakness of Travere Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 39%, being 455% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	332,352
Cost of Goods Sold	0
Intangible Assets	182,979
Liabilities, Current	83,262
Liabilities, Non-Current	4,010
Other Assets	7,364
Other Compr. Net Income	192
Other Expenses	18,470
Other Liabilities	130,243
Other Net Income	632
Property and Equipment	2,587
Research and Development	70,853
Revenues	133,591
Selling, General and Administrative Expense	92,803

Output Variable	Value in 1000 USD
Assets	525,282
Liabilities	217,515
Expenses	182,126
Stockholders Equity	307,767
Net Income	-47,903
Comprehensive Net Income	-47,807
Economic Capital Ratio	39%